SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-20-010023
Filing Date
2020-08-10
Accepted
2020-08-10 06:06:38
Documents
57
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20200630x10q.htm   iXBRL 10-Q 2144086
2 EX-31.1 tbph-20200630xex31d1.htm EX-31.1 13445
3 EX-31.2 tbph-20200630xex31d2.htm EX-31.2 14234
4 EX-32 tbph-20200630xex32.htm EX-32 15622
  Complete submission text file 0001558370-20-010023.txt   6834467

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20200630.xsd EX-101.SCH 40422
6 EX-101.CAL tbph-20200630_cal.xml EX-101.CAL 51457
7 EX-101.DEF tbph-20200630_def.xml EX-101.DEF 139145
8 EX-101.LAB tbph-20200630_lab.xml EX-101.LAB 380460
9 EX-101.PRE tbph-20200630_pre.xml EX-101.PRE 279530
10 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20200630x10q_htm.xml XML 1174442
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 201086923
SIC: 2834 Pharmaceutical Preparations